Eyebrow elevation using chemomodulation and myomodulation (Hyaluronic acid gel): A cohort analysis

This investigation aims to assess the clinical outcomes and patient-reported satisfaction associated with non-surgical eyebrow elevation utilizing botulinum toxin (BTX) and hyaluronic acid gel (HAG) formulations with G-prime fillers.

A retrospective analysis was conducted on a cohort of 460 subjects who underwent eyebrow elevation procedures from 2013 to 2024. The sample comprised 276 females (60%) and 184 males (40%), with a mean age of 50 years (standard deviation [SD] = 31.1 years). In the BTX group, 20 units were administered across five injection sites, including bilateral injections into the corrugator supercilii and a unilateral injection into the procerus muscle, with 0.1 mL (4 units) per site using 31-gauge needles. Pre- and 15-day post-procedure photographic evaluations were analyzed using Adobe Photoshop, and statistical analysis was performed with Microsoft Excel.

In the BTX cohort, the average increase in eyebrow height was 1.35 mm (range: 0.6-2.1 mm; SD = 1.06 mm), with a corresponding elevation from the medial limbus to the lateral brow edge averaging 1.35 mm (range: 1.0-1.7 mm; SD = 0.49 mm). The mean patient satisfaction score at 15 days post-treatment was similar for both groups: 1.73 for BTX and 1.71 for HAG, with no statistically significant difference observed (P = 0.9540).

Both BTX and HAG G-prime fillers demonstrate considerable efficacy in non-surgical brow elevation, enhancing eyebrow contour, and restoring youthful facial aesthetics. These minimally invasive interventions are viable alternatives to surgical brow-lifting techniques, yielding comparable patient-reported outcomes and satisfaction levels.